Funder
Centers for Disease Control and Prevention
Reference33 articles.
1. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern;Bright;Lancet,2005
2. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit;Byrn;Antimicrob. Agents Chemother.,2015
3. Methyl brevifolincarboxylate, a novel influenza virus PB2 inhibitor from Canarium Album (Lour.) Raeusch;Chen;Chem. Biol. Drug Des.,2020
4. Replicative fitness of seasonal influenza A viruses with decreased susceptibility to baloxavir;Chesnokov;J. Infect. Dis.,2020
5. Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2;Clark;J. Med. Chem.,2014
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献